Home › Myeloproliferative Neoplasms › Wisconsin › Madison
Myeloproliferative Neoplasms clinical trials in Madison, WI
3 studies for Myeloproliferative Neoplasms are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Myeloproliferative Neoplasms trials in other cities
- Houston, TX16 studies
- New York City, NY15 studies
- Boston, MA14 studies
- Milwaukee, WI10 studies
- Miami, FL10 studies
- Durham, NC9 studies
- Baldwin Park, CA9 studies
- Seattle, WA9 studies
- Chicago, IL9 studies
- Portland, OR8 studies
- Cleveland, OH8 studies
- Atlanta, GA8 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer23 studies
- Breast Cancer22 studies
- Metastatic Cancer21 studies
- Acute Myeloid Leukemia16 studies
- Non-Small Cell Lung Cancer16 studies
- Melanoma15 studies
- Cancer (all types)14 studies
- Ovarian Cancer13 studies
- Stomach Cancer11 studies
- Pancreatic Cancer10 studies
- Lung Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.